AR124928A2 - Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma - Google Patents

Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma

Info

Publication number
AR124928A2
AR124928A2 ARP220100361A ARP220100361A AR124928A2 AR 124928 A2 AR124928 A2 AR 124928A2 AR P220100361 A ARP220100361 A AR P220100361A AR P220100361 A ARP220100361 A AR P220100361A AR 124928 A2 AR124928 A2 AR 124928A2
Authority
AR
Argentina
Prior art keywords
ehv
vaccine
recombinant
composition
equine herpesvirus
Prior art date
Application number
ARP220100361A
Other languages
English (en)
Inventor
Jean Christophe Audonnet
Jules Maarten Minke
Nikolaus Osterrieder
Guanggang Ma
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of AR124928A2 publication Critical patent/AR124928A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16762—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones o vacunas que contienen un EHV-1 recombinante que produce una respuesta inmune en animales contra herpesvirus equino, incluyendo composiciones que comprenden dicho EHV-1 recombinante, métodos de vacunación contra herpesvirus equino, y conjuntos de componentes para usar con dichos métodos y composiciones. Reivindicación 1: Una composición o vacuna caracterizada porque comprende un Herpesvirus equino-1 (EHV-1) recombinante, en donde el EHV-1 comprende un gen mutado no funcional de Glicoproteína C (gC). Reivindicación 2: La composición o vacuna de la reivindicación 1, caracterizada porque el gen de Glicoproteína C mutada (gC) codifica para una proteína gC mutada, y en donde se elimina la región N-terminal de la proteína gC. Reivindicación 3: La composición o vacuna de la reivindicación 1, caracterizada porque se elimina el gen de gC. Reivindicación 4: La composición o vacuna de cualquiera de las reivindicaciones 1 a 3, caracterizada porque el EHV-1 recombinante comprende una polimerasa de ADN (Pol) que comprende una asparagina (N) en la posición de aminoácido 752. Reivindicación 5: Una composición o vacuna caracterizada porque comprende un EHV-1 recombinante, en donde el EHV-1 comprende un gen de polimerasa de ADN (Pol) que codifica para una Pol que comprende una asparagina (N) en la posición de aminoácido 752.
ARP220100361A 2012-03-20 2022-02-21 Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma AR124928A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261613151P 2012-03-20 2012-03-20

Publications (1)

Publication Number Publication Date
AR124928A2 true AR124928A2 (es) 2023-05-17

Family

ID=48193269

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130100918A AR090450A1 (es) 2012-03-20 2013-03-20 Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteina c mutada y usos de la misma
ARP220100361A AR124928A2 (es) 2012-03-20 2022-02-21 Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130100918A AR090450A1 (es) 2012-03-20 2013-03-20 Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteina c mutada y usos de la misma

Country Status (16)

Country Link
US (2) US8916371B2 (es)
EP (1) EP2827897B1 (es)
JP (1) JP6201166B2 (es)
CN (1) CN104302319B (es)
AR (2) AR090450A1 (es)
AU (1) AU2013235423B2 (es)
BR (1) BR112014023414B1 (es)
CA (1) CA2867893C (es)
ES (1) ES2711878T3 (es)
HK (1) HK1201205A1 (es)
HU (1) HUE042396T2 (es)
MX (1) MX355443B (es)
NZ (1) NZ700470A (es)
SG (1) SG11201405847SA (es)
UY (1) UY34695A (es)
WO (1) WO2013142371A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2899203B1 (en) * 2008-05-08 2019-07-10 Boehringer Ingelheim Animal Health USA Inc. Leishmania vaccine using sand fly salivary immunogen
US20130195918A1 (en) * 2011-08-08 2013-08-01 Dennis J. O'Callaghan Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof
WO2015073507A1 (en) * 2013-11-13 2015-05-21 Cornell University Stimulation of neonatal immunity
WO2015123307A1 (en) 2014-02-11 2015-08-20 University Of Miami Methods and compositions for transgene expression in a herpesvirus vector system
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
RU2736472C2 (ru) * 2016-11-18 2020-11-17 Общество с ограниченной ответственностью "ЭКСИФАРМ" Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк
US11447562B2 (en) 2017-01-01 2022-09-20 Chi-Yu Gregory Lee RP215 chimeric antigen receptor construct and methods of making and using same
US11084272B2 (en) 2017-05-31 2021-08-10 General Electric Company Test structure for additive manufacture and related method for emitter alignment

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69417717T2 (de) * 1993-12-20 1999-10-07 Akzo Nobel Nv Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
GB9625968D0 (en) * 1996-12-13 1997-01-29 Univ Glasgow Vaccine
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
RS50325B (sr) 1999-09-25 2009-09-08 University Of Iowa Research Foundation, Imunostimulatorne nukleinske kiseline
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
MXPA03000823A (es) * 2000-07-27 2003-09-10 Res Corp Technologies Inc Vacunas para el virus del herpes simple equino del tipo 1: mutaciones de los viruses que se refugian dentro del gen precoz inmediato.
US20030059934A1 (en) * 2001-04-03 2003-03-27 Nikolaus Osterrieder Artificial chromosomes comprising EHV sequences
DE10116594A1 (de) * 2001-04-03 2002-10-10 Boehringer Ingelheim Vetmed Künstliche Chromosomen, die EHV-Sequenzen umfassen
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US7078507B2 (en) 2001-11-09 2006-07-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Synthetic genes for malarial proteins and methods of use
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
WO2004011677A2 (en) * 2002-07-26 2004-02-05 Animal Health Trust Viral marker
EP1394258A1 (en) * 2002-08-30 2004-03-03 Geneart GmbH Non-human herpesviruses as vectors
EP1765387B1 (en) 2004-06-04 2013-01-09 Merial Limited NEEDLE-FREE ADMINISTRATION OF FeLV VACCINES
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines

Also Published As

Publication number Publication date
CN104302319A (zh) 2015-01-21
HUE042396T2 (hu) 2019-06-28
AU2013235423B2 (en) 2017-03-30
US20130251747A1 (en) 2013-09-26
US20150190502A1 (en) 2015-07-09
JP2015512395A (ja) 2015-04-27
MX355443B (es) 2018-04-18
US8916371B2 (en) 2014-12-23
BR112014023414A8 (pt) 2022-07-05
BR112014023414A2 (pt) 2017-07-11
CA2867893C (en) 2022-09-20
CA2867893A1 (en) 2013-09-26
HK1201205A1 (en) 2015-08-28
EP2827897B1 (en) 2018-10-31
AR090450A1 (es) 2014-11-12
BR112014023414B1 (pt) 2022-08-30
NZ700470A (en) 2016-04-29
AU2013235423A1 (en) 2014-10-16
ES2711878T3 (es) 2019-05-08
CN104302319B (zh) 2016-08-24
US9555101B2 (en) 2017-01-31
UY34695A (es) 2013-10-31
JP6201166B2 (ja) 2017-09-27
EP2827897A1 (en) 2015-01-28
SG11201405847SA (en) 2014-10-30
MX2014011281A (es) 2015-05-11
WO2013142371A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
AR124928A2 (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
PH12018500855A1 (en) Herpes simplex virus vaccine
AR102527A1 (es) Vacunas terapéuticas para hpv16
AR061484A1 (es) Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
CO2017007105A2 (es) Nuevos virus de tilapia
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
DOP2012000187A (es) Antigeno ndv recombinante y usos del mismo
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
NZ598605A (en) Vaccine against african horse sickness virus
UY33523A (es) ?vectores de parapoxvirus?.
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
AR092939A1 (es) Vacuna contra cooperia
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
AR073595A1 (es) Vacunas que contienen variantes geneticas de parvovirus canino
AR105775A1 (es) Vacunas terapéuticas contra el hpv18
AR109240A1 (es) Vacuna contra dirofilaria immitis, métodos y usos de la misma